廖偉智 Wei-Chih Liao

國立臺灣大學醫學院
內科教授

學歷

國立臺灣大學流行病學與預防醫學研究所博士(2014)
國立臺灣大學流行病學研究所碩士(2009)
國立臺灣大學醫學系醫學士(2005)

經歷

國立臺灣大學醫學院附設醫院綜合診療部部主任(2024/8~迄今)
國立臺灣大學醫學院醫學系內科教授(2020/8~迄今)
國立臺灣大學醫學院附設醫院內科主治醫師(2005/8~迄今)

個人勵志銘

TEAM = Together Everyone Achieves More.

首創AI胰臟癌偵測獲美國突破性醫療器材認證

Pancreatic cancer (PC), the most lethal cancer, is the 7th leading cause of cancer deaths in Taiwan and projected to become the second leading cause of cancer deaths in the US by 2030. My research focuses on early detection of pancreatic cancer (PC) through artificial intelligence (AI)-assisted medical image analysis and novel biomarkers. To enable detection of occult early PC, I have developed the world’s first computer-aided detection/diagnosis (CADe/x) tool for PC. This AI-based breakthrough SaMD has been approved by Taiwan FDA and received multiple US and Taiwan patents. I have also discovered novel PC-produced factors that mediate PC-associated diabetes and cachexia, facilitating early detection of PC. By enhancing detection of early PCs, my research may help reduce PC-related healthcare costs and socioeconomic burden and contribute to the national goal of developing AI healthcare industry and creating new economic values.

傑出研究獎

得獎感言

能獲獎不僅是我個人的莫大榮耀，更是對我們團隊的鼓勵與肯定。我衷心感謝我的研究團隊和同仁們，因爲他們的支持與付出，才讓我得以獲獎。胰臟疾病是比較少人感興趣的領域，過程中充滿困難與挑戰。感謝師長們的指導與啟發，同事與團隊的幫忙與支持，讓我得以逐漸成長，克服種種挑戰。

感謝國家科學及技術委員會長期的支持，讓我們得以由一開始的基礎研究進展到產品開發，再進一步完成醫材取證及實際商轉，讓我們的研究成果能夠在實際臨床場域獲得應用。希望我們的研究成果能夠幫助病患，個人的經驗也可以對其他有類似研究興趣的研究者有些幫助。